Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 10/20 | 0.34 |
| ▸ | MMP10 | P09238 | 5/20 | 0.34 |
| ▸ | MMP8 | P22894 | 5/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 4/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | SENP5 | Q96HI0 | 2/20 | 0.32 |
| ▸ | SENP2 | Q9HC62 | 2/20 | 0.32 |
| ▸ | SENP1 | Q9P0U3 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL63639 | 0.87 | CYP2C9 (0.45) | MMP13MMP10MMP8CYP2C9MMP9 | |
| SCHEMBL62850 | 0.87 | CYP2C9 (0.45) | MMP13MMP10MMP8CYP2C9MMP9 | |
| SCHEMBL63663 | 0.87 | CYP2C9 (0.45) | MMP13MMP10MMP8CYP2C9MMP9 | |
| SCHEMBL62840 | 0.87 | CYP2C9 (0.41) | CYP2C9PDE5ASMN1; SMN2 | |
| SCHEMBL64360 | 0.86 | CYP2C9 (0.40) | CYP2C9SENP5SENP2SENP1SMN1; SMN2 | |
| SCHEMBL14212563 | 0.85 | MMP13 (0.35) | MMP13MMP10MMP8CYP2C9PDE5A | |
| SCHEMBL14212564 | 0.84 | MMP13 (0.34) | MMP13MMP10MMP8CYP2C9PDE5A | |
| SCHEMBL14234487 | 0.82 | MAPK1 (0.33) | MMP13MMP10MMP8CYP2C9 | |
| SCHEMBL62502 | 0.82 | CYP2C9 (0.46) | MMP13CYP2C9 | |
| SCHEMBL63992 | 0.81 | CYP2C9 (0.44) | MMP13MMP10MMP8CYP2C9MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | MMP13 4137/4885MMP10 2158/4885MMP8 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.